332 related articles for article (PubMed ID: 27997974)
21. PSC associated inflammatory bowel disease: a distinct entity.
Beheshti-Maal A; Tamimi A; Iravani S; Memarnejadian A; Sorouri M; Aghdaei HA; Zali MR; Hossein Khannazer N; Vosough M
Expert Rev Gastroenterol Hepatol; 2022 Feb; 16(2):129-139. PubMed ID: 35078376
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the gut microbiota in patients with primary sclerosing cholangitis compared to inflammatory bowel disease and healthy controls.
Ostadmohammadi S; Azimirad M; Houri H; Naseri K; Javanmard E; Mirjalali H; Yadegar A; Sadeghi A; Asadzadeh Aghdaei H; Zali MR
Mol Biol Rep; 2021 Jul; 48(7):5519-5529. PubMed ID: 34304365
[TBL] [Abstract][Full Text] [Related]
23. Primary sclerosing cholangitis associated with inflammatory bowel disease: an update.
Rossi RE; Conte D; Massironi S
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):123-31. PubMed ID: 26636407
[TBL] [Abstract][Full Text] [Related]
24. Pathogenesis and clinical spectrum of primary sclerosing cholangitis.
Gidwaney NG; Pawa S; Das KM
World J Gastroenterol; 2017 Apr; 23(14):2459-2469. PubMed ID: 28465630
[TBL] [Abstract][Full Text] [Related]
25. Current management of primary sclerosing cholangitis in pediatric patients.
Ibrahim SH; Lindor KD
Paediatr Drugs; 2011 Apr; 13(2):87-95. PubMed ID: 21351808
[TBL] [Abstract][Full Text] [Related]
26. Hepatobiliary manifestations of inflammatory bowel disease.
Raj V; Lichtenstein DR
Gastroenterol Clin North Am; 1999 Jun; 28(2):491-513. PubMed ID: 10372279
[TBL] [Abstract][Full Text] [Related]
27. Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).
Mattner J
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834858
[TBL] [Abstract][Full Text] [Related]
28. Primary sclerosing cholangitis: etiopathogenesis and clinical management.
Gupta A; Bowlus CL
Front Biosci (Elite Ed); 2012 Jan; 4(5):1683-705. PubMed ID: 22201985
[TBL] [Abstract][Full Text] [Related]
29. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.
Li Y; Tang R; Leung PSC; Gershwin ME; Ma X
Autoimmun Rev; 2017 Sep; 16(9):885-896. PubMed ID: 28698093
[TBL] [Abstract][Full Text] [Related]
30. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.
Kummen M; Holm K; Anmarkrud JA; Nygård S; Vesterhus M; Høivik ML; Trøseid M; Marschall HU; Schrumpf E; Moum B; Røsjø H; Aukrust P; Karlsen TH; Hov JR
Gut; 2017 Apr; 66(4):611-619. PubMed ID: 26887816
[TBL] [Abstract][Full Text] [Related]
31. The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies.
Özdirik B; Müller T; Wree A; Tacke F; Sigal M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203536
[TBL] [Abstract][Full Text] [Related]
32. Gut Microbiome of Children and Adolescents With Primary Sclerosing Cholangitis in Association With Ulcerative Colitis.
Cortez RV; Moreira LN; Padilha M; Bibas MD; Toma RK; Porta G; Taddei CR
Front Immunol; 2020; 11():598152. PubMed ID: 33613519
[TBL] [Abstract][Full Text] [Related]
33. Primary sclerosing cholangitis - a comprehensive review.
Karlsen TH; Folseraas T; Thorburn D; Vesterhus M
J Hepatol; 2017 Dec; 67(6):1298-1323. PubMed ID: 28802875
[TBL] [Abstract][Full Text] [Related]
34. Role of the microbiota and antibiotics in primary sclerosing cholangitis.
Tabibian JH; Talwalkar JA; Lindor KD
Biomed Res Int; 2013; 2013():389537. PubMed ID: 24232746
[TBL] [Abstract][Full Text] [Related]
35. Emerging pharmacologic therapies for primary sclerosing cholangitis.
Cheung AC; Lazaridis KN; LaRusso NF; Gores GJ
Curr Opin Gastroenterol; 2017 May; 33(3):149-157. PubMed ID: 28257308
[TBL] [Abstract][Full Text] [Related]
36. The features of mucosa-associated microbiota in primary sclerosing cholangitis.
Torres J; Bao X; Goel A; Colombel JF; Pekow J; Jabri B; Williams KM; Castillo A; Odin JA; Meckel K; Fasihuddin F; Peter I; Itzkowitz S; Hu J
Aliment Pharmacol Ther; 2016 Apr; 43(7):790-801. PubMed ID: 26857969
[TBL] [Abstract][Full Text] [Related]
37. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II.
Rossen NG; Fuentes S; Boonstra K; D'Haens GR; Heilig HG; Zoetendal EG; de Vos WM; Ponsioen CY
J Crohns Colitis; 2015 Apr; 9(4):342-8. PubMed ID: 25547975
[TBL] [Abstract][Full Text] [Related]
38. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis.
Nakamoto N; Sasaki N; Aoki R; Miyamoto K; Suda W; Teratani T; Suzuki T; Koda Y; Chu PS; Taniki N; Yamaguchi A; Kanamori M; Kamada N; Hattori M; Ashida H; Sakamoto M; Atarashi K; Narushima S; Yoshimura A; Honda K; Sato T; Kanai T
Nat Microbiol; 2019 Mar; 4(3):492-503. PubMed ID: 30643240
[TBL] [Abstract][Full Text] [Related]
39. Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis.
Bjarnason I; Hayee B; Pavlidis P; Kvasnovsky C; Scalori A; Sisson G; Charlesworth A; Shaikh H; Bjornsson E; Heneghan MA
EBioMedicine; 2015 Oct; 2(10):1523-7. PubMed ID: 26629548
[TBL] [Abstract][Full Text] [Related]
40. Intestinal microbiota in primary sclerosing cholangitis.
Hov JR; Kummen M
Curr Opin Gastroenterol; 2017 Mar; 33(2):85-92. PubMed ID: 28030369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
